Literature DB >> 31217190

How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.

Marshall A Mazepa1, Camila Masias2, Shruti Chaturvedi3.   

Abstract

Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31217190     DOI： 10.1182/blood.2019000954

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  13 in total

1.  Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Pranay Sinha; Jeanne E Hendrickson; Christopher Tormey; Pavan K Bendapudi; Alfred Ian Lee
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

2.  Counting the cost of caplacizumab.

Authors:  Shruti Chaturvedi
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

3.  ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.

Authors:  Linus A Völker; Jessica Kaufeld; Wolfgang Miesbach; Sebastian Brähler; Martin Reinhardt; Lucas Kühne; Anja Mühlfeld; Adrian Schreiber; Jens Gaedeke; Markus Tölle; Wolfram J Jabs; Fedai Özcan; Silke Markau; Matthias Girndt; Frederic Bauer; Timm H Westhoff; Helmut Felten; Martin Hausberg; Marcus Brand; Jens Gerth; Markus Bieringer; Martin Bommer; Stefan Zschiedrich; Johanna Schneider; Saban Elitok; Alexander Gawlik; Anja Gäckler; Andreas Kribben; Vedat Schwenger; Ulf Schoenermarck; Maximilian Roeder; Jörg Radermacher; Jörn Bramstedt; Anke Morgner; Regina Herbst; Ana Harth; Sebastian A Potthoff; Charis von Auer; Ralph Wendt; Hildegard Christ; Paul T Brinkkoetter; Jan Menne
Journal:  Blood Adv       Date:  2020-07-14

4.  Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil.

Authors:  F Fioredda; E Cappelli; A Mariani; A Beccaria; E Palmisani; A Grossi; I Ceccherini; R Venè; C Micalizzi; M Calvillo; F Pierri; I Mancini; F Peyvandi; F Corsolini; C Dufour; M Miano
Journal:  Blood Adv       Date:  2019-11-12

5.  Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.

Authors:  Kazuya Sakai; Tatsuhiko Someya; Kaori Harada; Hideo Yagi; Taei Matsui; Masanori Matsumoto
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

Review 6.  Upfront rituximab therapy for thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a case-based review.

Authors:  Tomoyuki Mutoh; Keiichi Ohashi; Taichi Nagai; Akira Sugiura; Masataka Kudo; Hiroshi Fujii
Journal:  Rheumatol Int       Date:  2022-08-12       Impact factor: 3.580

Review 7.  Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review.

Authors:  Shen-Ju Liang; Quan-You Zheng; Meng-Shan Li; Ming-Ye Lv; Wen-Ting Chen; Yi Yang
Journal:  Clin Rheumatol       Date:  2022-05-07       Impact factor: 3.650

8.  Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.

Authors:  Teresa Marta Cardesa-Salzmann; Bernhard Stephan; Arne Simon; Rhoikos Furtwängler; Dominik Schöndorf; Sabine Heine; Eyad Torfah; Margaux Lux; Sonja Meyer; Norbert Graf
Journal:  Clin Case Rep       Date:  2022-05-20

Review 9.  Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature.

Authors:  Kaori Uchino; Kazuya Sakai; Saki Shinohara; Akifumi Matsuhisa; Yusuke Iida; Yuta Nakano; Saori Matsumura; Jo Kanasugi; Soichi Takasugi; Ayano Nakamura; Tomohiro Horio; Satsuki Murakami; Shohei Mizuno; Hidesuke Yamamoto; Ichiro Hanamura; Masanori Matsumoto; Akiyoshi Takami
Journal:  Int J Hematol       Date:  2022-03-10       Impact factor: 2.319

10.  Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.

Authors:  Cai Yue; Jian Su; Xiaohong Fan; Li Song; Wei Jiang; Jinghua Xia; Tao Shi; Xuan Zhang; Xuemei Li
Journal:  Orphanet J Rare Dis       Date:  2020-08-28       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.